Please use this identifier to cite or link to this item:
|Title:||Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore|
Hepatitis B virus infection
Hepatitis C virus infection
Primary hepatocellular carcinoma
|Citation:||Khin, L.W., Teo, C.J., Guan, R. (1996-10). Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore. Singapore Medical Journal 37 (5) : 492-496. ScholarBank@NUS Repository.|
|Abstract:||The prevalence of hepatitis B and C serological markers were studied in 55 patients (45 males and 10 females) with primary hepatocellular carcinoma (PHC), Their ages ranged from 28 years to 79 years (mean age: 56 years). Fifty-five other patients with non-hepatic diseases were used as age and sex matched controls. Forty-one PHC patients (74%) had chronic hepatitis B infection alone, 5 patients (9%) had chronic hepatitis C infection alone, 6 patients (11%) had chronic hepatitis B and C co-infection, 2 patients (4%) had evidence of previous exposure to HBV and one patient (2%) had no hepatitis B and C serological markers. Among those patients with chronic HBV infection alone, the commonest serological pattern was HBsAg and anti-HBe positive (66%;27/41) followed by HBsAg and HBeAg positive (i.e. highly HBV infectious group) (24%;10/41). All the positivity rate for HBsAg (including co-infection with HBV and HCV) was 85% and all the positivity rate for anti-HCV (including co-infection with HBV and HCV) was 20%. In the control group, positivity rate for HBsAg was 13% (7/55). None of the control sera was positive for anti-HCV. Positivity rates for HBsAg and anti-HCV were significantly higher in the 55 PHC cases than in controls. The odds ratio for HBsAg was 40.3 (p value:|
|Source Title:||Singapore Medical Journal|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 6, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.